U.S. Markets closed
  • S&P Futures

    4,229.00
    +6.75 (+0.16%)
     
  • Dow Futures

    33,851.00
    +46.00 (+0.14%)
     
  • Nasdaq Futures

    14,203.00
    +37.50 (+0.26%)
     
  • Russell 2000 Futures

    2,288.50
    +4.00 (+0.18%)
     
  • Crude Oil

    70.41
    -0.63 (-0.89%)
     
  • Gold

    1,786.80
    +12.00 (+0.68%)
     
  • Silver

    26.27
    +0.42 (+1.62%)
     
  • EUR/USD

    1.1927
    +0.0017 (+0.1431%)
     
  • 10-Yr Bond

    1.5110
    -0.0580 (-3.70%)
     
  • Vix

    17.75
    -0.40 (-2.20%)
     
  • GBP/USD

    1.3928
    +0.0003 (+0.0251%)
     
  • USD/JPY

    110.1700
    -0.0610 (-0.0553%)
     
  • BTC-USD

    37,933.96
    -950.93 (-2.45%)
     
  • CMC Crypto 200

    941.84
    -28.04 (-2.89%)
     
  • FTSE 100

    7,153.43
    -31.52 (-0.44%)
     
  • Nikkei 225

    29,057.51
    +39.18 (+0.14%)
     

Novavax agrees on expansion of COVID-19 vaccine production in South Korea

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

May 22 (Reuters) - Novavax Inc said on Saturday it has signed an agreement with South Korea's SK Bioscience Co Ltd and the government to expand its production of vaccines, including the U.S. drug developer's protein-based COVID-19 vaccine candidate.

The latest agreement is in addition to an existing manufacturing and licensing deal, intended to provide wider access to NVX-CoV2373 in South Korea and globally, Novavax said in a press release.

(Reporting by Maria Ponnezhath in Bengaluru; editing by Diane Craft)